ArticleNucleic acids research2026
A hybrid RNA-based reporter assay for robust quantification of cytidine deaminase activity.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
We developed a robust, hybrid RNA-based reporter assay for the quantification of cytidine deaminase (CDA) activity, overcoming limitations of current methods often compromised by interferences in crude biological samples. Our two-step method physically separates the enzymatic reaction in cell lysates from a highly specific detection step in a selected and validated CDA-deficient reporter cell line (143B cell line). This design confers exceptional robustness, eliminating the need for sample purification. In the first step, a cell lysate converts 5-fluorocytidine to 5-fluorouridine. After heat inactivation of lysate proteins, 5-fluorouridine is quantified by its incorporation into reporter cell RNA, yielding a highly specific fluorescent signal. The detection limit of a formed product in the assay achieves 2.7 µM. The assay shows good correlation with LC-MS data, and its adaptability to a multi-well plate format makes it an ideal and cost-effective tool for high-throughput screening. We further applied this assay to reveal that CDA-positive cells actively secrete 5-fluorouridine, providing quantitative evidence for a potential therapeutic bystander effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.